When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ACRS - With One Late-Stage Study Out Of The Way Aclaris Moves One Inch Closer To Commercialization
Aclaris Therapeutics Inc.
Aclaris Therapeutics (ACRS) announced that it had obtained positive resultsin a Phase 3 study using A-101 45% topical solution to treat patients with common warts (also known as verruca vulgaris). With this being the first of two Phase 3 studies, there is another late-stage trial readout expected in Q4 of 2019. With positive data on hand from both late-stage studies, the biotech will soon be able to file an NDA for approval of A-101 45%. This is a highly important step for the company as it seeks to get its product approved